Search Result

Results for "

Iks

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Biochemical Assay Reagents (1) Calcium Channel (3) CFTR (1) Endogenous Metabolite (1) Isotope-Labeled Compounds (3) Potassium Channel (15) Reference Standards (1) Sodium Channel (3)
By Research Areas:	Cardiovascular Disease (14) Inflammation/Immunology (1) Metabolic Disease (4) Neurological Disease (2)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16953

JNJ 303 1 Publications Verification	Potassium Channel	Cardiovascular Disease Neurological Disease
JNJ-303 is a specific delayed rectifier Kv blocker. JNJ 303 can potent block I_Ks with an IC₅₀ value of 64 nM. JNJ-303 can be used for the research of diabetes, obesity and central nervous system .

HY-108591

L-364,373 R-L3	Potassium Channel	Cardiovascular Disease
L-364,373 (R-L3) is a voltage-gated Kv7.1 (KCNQ1)/mink channels activator. L-364,373 activates Iks (slow delayed rectifier potassium current) and shortens action potential duration in guinea pig cardiac myocytes, and suppresses early afterdepolarizations in rabbit ventricular myocytes .

HY-106369

HMR 1556 2 Publications Verification	Potassium Channel	Cardiovascular Disease
HMR 1556, a chromanol derivative, is a potent *I_Ks* blocker with IC₅₀s of 10.5 nM and 34 nM in canine and guinea pig left ventricular myocytes, respectively .

HY-108575

Chromanol 293B	Potassium Channel CFTR	Cardiovascular Disease
Chromanol 293B is a selective blocker of the slow delayed rectifier K ⁺ current (IKs) with IC₅₀ of 1-10 μM and a weak inhibitor of KATP channel. Chromanol 293B also blocks the CFTR chloride current with an IC₅₀ of 19 μM .

HY-121977

IKs124	Potassium Channel	Inflammation/Immunology
IKs124 is KCNE2/KCNQ1 potassium channel blocker with the with an IC₅₀ of 8 nM. IKs124 can be used for study of peptic ulcers .

HY-N15937

IKS02	Biochemical Assay Reagents	Others
IKS02, a phosphatidylcholine (PC) phospholipid, is a photoaffinity labeling (PAL) probe .

HY-121520

Docosahexaenoyl glycine	Potassium Channel Endogenous Metabolite	Cardiovascular Disease
Docosahexaenoyl glycine is a PUFA analogue. Docosahexaenoyl glycine has activating effects on IKs channels and restore the function of IKs channels with LQT1 mutation .

HY-18600B

(E)-Azimilide (E)-NE-10064	Potassium Channel	Cardiovascular Disease
(E)-Azimilide is an isomer of Azimilide (HY-18600), a class of antiarrhythmic compounds that inhibit I(Ks) and I(Kr) activity .

HY-110015

(-)-Chromanol 293B	Potassium Channel	Cardiovascular Disease
(-)-Chromanol 293B is a potent and selective inhibitor of the slow component of delayed rectifier K ⁺ current (IKs). (-)-Chromanol 293B can be used for the research of antiarrhythmic .

HY-118387

AVE-0118	Potassium Channel	Neurological Disease
AVE-0118 is a nonselective Kv1.5 blocker with an IC₅₀ of 1.1 μM. AVE-0118 is a multichannel inhibitor with weak, micromolar activity against Kv1.5 and other ion channels. It is inactive against I_Ks, I_KATP, and L-type Ca+ channels .

HY-106577

Cibenzoline Cifenline; Ro 22-7796	Potassium Channel	Cardiovascular Disease Metabolic Disease
Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a K_ATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC₅₀ of 22.2 μM. Cibenzoline inhibits I_Kr and I_Ks currents with IC₅₀ values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .

HY-106577R

Cibenzoline (Standard) Cifenline (Standard); Ro 22-7796 (Standard)	Reference Standards Potassium Channel	Cardiovascular Disease Metabolic Disease
Cibenzoline (Standard) is the analytical standard of Cibenzoline. This product is intended for research and analytical applications. Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a K_ATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC₅₀ of 22.2 μM. Cibenzoline inhibits I_Kr and I_Ks currents with IC₅₀ values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .

HY-106577S

Cibenzoline-d4 Cifenline-d₄; Ro 22-7796-d₄	Isotope-Labeled Compounds Potassium Channel	Cardiovascular Disease Metabolic Disease
Cibenzoline-d₄ (Cifenline-d₄) is deuterium labeled Cibenzoline. Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a K_ATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC₅₀ of 22.2 μM. Cibenzoline inhibits I_Kr and I_Ks currents with IC₅₀ values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .

HY-106577S1

Cibenzoline-d5 Cifenline-d₅; Ro 22-7796-d₅	Isotope-Labeled Compounds	Cardiovascular Disease Metabolic Disease
Cibenzoline-d₅ (Cifenline-d₅) is deuterium labeled Cibenzoline. Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a K_ATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC₅₀ of 22.2 μM. Cibenzoline inhibits I_Kr and I_Ks currents with IC₅₀ values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .

HY-18600A

Azimilide dihydrochloride 2 Publications Verification NE-10064 dihydrochloride	Potassium Channel Calcium Channel Sodium Channel	Cardiovascular Disease
Azimilide (NE-10064) dihydrochloride is a class III antiarrhythmic agent, which works by blocking potassium channels in the heart. Azimilide dihydrochloride is a dual blocker of *I_Ks* (IC₅₀ = 2.6 μM (2mM [K⁺]ₑ)) and I_Kr (IC₅₀ = 1 μM (4 mM [K⁺])). Azimilide dihydrochloride blocked HERG channel at 0.1 and 1 Hz with IC₅₀s of 1.4 μM and 5.2 μM respectively. Azimilide dihydrochloride also inhibits L-type calcium current (I_Ca) (IC₅₀ = 17.8 μM) and sodium current (I_Na) (IC₅₀ = 19 μM). Azimilide dihydrochloride can be used for the study of atrial fibrillation and ventricular fibrillation .

HY-18600

Azimilide 2 Publications Verification NE-10064	Potassium Channel Calcium Channel Sodium Channel	Cardiovascular Disease
Azimilide (NE-10064) is a class III antiarrhythmic agent, which works by blocking potassium channels in the heart. Azimilide is a dual blocker of *I_Ks* (IC₅₀ = 2.6 μM (2mM [K⁺]ₑ)) and I_Kr (IC₅₀ = 1 μM (4 mM [K⁺])). Azimilide blocked HERG channel at 0.1 and 1 Hz with IC₅₀s of 1.4 μM and 5.2 μM respectively. Azimilide also inhibits L-type calcium current (I_Ca) (IC₅₀ = 17.8 μM) and sodium current (I_Na) (IC₅₀ = 19 μM). Azimilide can be used for the study of atrial fibrillation and ventricular fibrillation .

HY-18600AS

Azimilide-d8 dihydrochloride NE-10064-dd₈ dihydrochloride	Isotope-Labeled Compounds Potassium Channel Calcium Channel Sodium Channel	Cardiovascular Disease
Azimilide-d₈ (NE-10064-d₈) dihydrochloride is the deuterium labeled Azimilide dihydrochloride (HY-18600A). Azimilide dihydrochloride is a class III antiarrhythmic agent, which works by blocking potassium channels in the heart. Azimilide dihydrochloride is a dual blocker of *I_Ks* (IC₅₀ = 2.6 μM (2mM [K⁺]ₑ)) and I_Kr (IC₅₀ = 1 μM (4 mM [K⁺])). Azimilide dihydrochloride blocked HERG channel at 0.1 and 1 Hz with IC₅₀s of 1.4 μM and 5.2 μM respectively. Azimilide dihydrochloride also inhibits L-type calcium current (I_Ca) (IC₅₀ = 17.8 μM) and sodium current (I_Na) (IC₅₀ = 19 μM). Azimilide dihydrochloride can be used for the study of atrial fibrillation and ventricular fibrillation .

Docosahexaenoyl glycine	Potassium Channel Endogenous Metabolite	Cardiovascular Disease
Docosahexaenoyl glycine is a PUFA analogue. Docosahexaenoyl glycine has activating effects on IKs channels and restore the function of IKs channels with LQT1 mutation .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N15937

IKS02	Lipid	Biochemical Assay Reagents
IKS02, a phosphatidylcholine (PC) phospholipid, is a photoaffinity labeling (PAL) probe .

HY-121520

Docosahexaenoyl glycine	Cardiovascular Disease Alkaloids Classification of Application Fields Ketones, Aldehydes, Acids Other Alkaloids Source classification Endogenous metabolite Disease Research Fields	Potassium Channel Endogenous Metabolite
Docosahexaenoyl glycine is a PUFA analogue. Docosahexaenoyl glycine has activating effects on IKs channels and restore the function of IKs channels with LQT1 mutation .

Cat. No.	Product Name	Chemical Structure

HY-106577S

Cibenzoline-d4
Cibenzoline-d₄ (Cifenline-d₄) is deuterium labeled Cibenzoline. Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a K_ATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC₅₀ of 22.2 μM. Cibenzoline inhibits I_Kr and I_Ks currents with IC₅₀ values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .

Cibenzoline-d4

Cibenzoline-d₄ (Cifenline-d₄) is deuterium labeled Cibenzoline. Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a K_ATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC₅₀ of 22.2 μM. Cibenzoline inhibits I_Kr and I_Ks currents with IC₅₀ values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .

HY-106577S1

Cibenzoline-d5
Cibenzoline-d₅ (Cifenline-d₅) is deuterium labeled Cibenzoline. Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a K_ATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC₅₀ of 22.2 μM. Cibenzoline inhibits I_Kr and I_Ks currents with IC₅₀ values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .

Cibenzoline-d5

Cibenzoline-d₅ (Cifenline-d₅) is deuterium labeled Cibenzoline. Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a K_ATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC₅₀ of 22.2 μM. Cibenzoline inhibits I_Kr and I_Ks currents with IC₅₀ values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .

HY-18600AS

Azimilide-d8 dihydrochloride
Azimilide-d₈ (NE-10064-d₈) dihydrochloride is the deuterium labeled Azimilide dihydrochloride (HY-18600A). Azimilide dihydrochloride is a class III antiarrhythmic agent, which works by blocking potassium channels in the heart. Azimilide dihydrochloride is a dual blocker of *I_Ks* (IC₅₀ = 2.6 μM (2mM [K⁺]ₑ)) and I_Kr (IC₅₀ = 1 μM (4 mM [K⁺])). Azimilide dihydrochloride blocked HERG channel at 0.1 and 1 Hz with IC₅₀s of 1.4 μM and 5.2 μM respectively. Azimilide dihydrochloride also inhibits L-type calcium current (I_Ca) (IC₅₀ = 17.8 μM) and sodium current (I_Na) (IC₅₀ = 19 μM). Azimilide dihydrochloride can be used for the study of atrial fibrillation and ventricular fibrillation .

Azimilide-d8 dihydrochloride

Azimilide-d₈ (NE-10064-d₈) dihydrochloride is the deuterium labeled Azimilide dihydrochloride (HY-18600A). Azimilide dihydrochloride is a class III antiarrhythmic agent, which works by blocking potassium channels in the heart. Azimilide dihydrochloride is a dual blocker of I_Ks (IC₅₀ = 2.6 μM (2mM [K⁺]ₑ)) and I_Kr (IC₅₀ = 1 μM (4 mM [K⁺])). Azimilide dihydrochloride blocked HERG channel at 0.1 and 1 Hz with IC₅₀s of 1.4 μM and 5.2 μM respectively. Azimilide dihydrochloride also inhibits L-type calcium current (I_Ca) (IC₅₀ = 17.8 μM) and sodium current (I_Na) (IC₅₀ = 19 μM). Azimilide dihydrochloride can be used for the study of atrial fibrillation and ventricular fibrillation .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks